Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_assertion type Assertion NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_head.
- NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_assertion description "[Finally, SLC16A12, GALR2, TOX, SPOCK2, EGFR5 and DPYS are candidate biomarkers for breast cancer (methylation range 33%-79%) with the combination of EGFR5 or TOX hypermethylation showing a sensitivity of 92% and specificity of 92%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_provenance.
- NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_assertion evidence source_evidence_literature NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_provenance.
- NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_assertion SIO_000772 18446232 NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_provenance.
- NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_assertion wasDerivedFrom befree-2016 NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_provenance.
- NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_assertion wasGeneratedBy ECO_0000203 NP668564.RAhv5uERBmHpT1BEYbpVZfZOOooFgVM92eNii0F46to-M130_provenance.